The
Shuman Law Firm today announced that it is investigating potential
claims against certain officers and directors of directors of DaVita,
Inc. (“DaVita” or the “Company”) (NYSE: DVA). DaVita provides kidney
dialysis and administrative services, including related laboratory
services for medical facilities across the United States. DaVita’s
dialysis and related laboratory services business accounts for
approximately 93% of the Company’s consolidated net operating revenues.
DaVita is the subject of two qui tam lawsuits which allege that
DaVita executives have, for many years, systemically overprescribed
patients their medications related to kidney dialysis in order to
receive the maximum reimbursement from the federal government. These
actions have purportedly cost taxpayers millions of dollars in illegal
and unjustified payments to DaVita. DaVita is also currently being
investigated by multiple U.S. Attorneys, the U.S. Department of Justice
and the U.S. Department of Health and Human Services regarding these
claims.
If you currently own DaVita common stock and are interested in
discussing your rights as a shareholder, or have information relating to
this investigation, please contact Kip B. Shuman or Rusty E. Glenn
toll-free at (866) 974-8626 or email Mr. Shuman at kip@shumanlawfirm.com
or email Mr. Glenn at rusty@shumanlawfirm.com.
The Shuman Law Firm represents investors throughout the nation,
concentrating its practice in securities class actions and shareholder
derivative actions.
